Top Page
Zhaoke Ophthalmology Ltd.
(6622)
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Zhaoke Ophthalmology Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 69.32M | 18.75M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 51.80M | 14.25M | 0.00 | 0.00 | 0.00 |
| EBITDA | -251.23M | -327.86M | -369.10M | -377.53M | -100.70M |
| Net Income | -237.49M | -385.04M | -410.46M | -2.13B | -728.64M |
Balance Sheet | |||||
| Total Assets | 2.24B | 2.42B | 2.57B | 2.61B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 1.19B | 1.46B | 1.73B | 2.14B | 871.34M |
| Total Debt | 238.59M | 238.03M | 131.93M | 37.03M | 37.53M |
| Total Liabilities | 343.44M | 372.02M | 222.25M | 109.92M | 1.97B |
| Stockholders Equity | 1.90B | 2.05B | 2.35B | 2.50B | -745.97M |
Cash Flow | |||||
| Free Cash Flow | -297.79M | -418.93M | -569.60M | -339.63M | -279.38M |
| Operating Cash Flow | -253.72M | -323.66M | -331.05M | -245.14M | -103.42M |
| Investing Cash Flow | -116.45M | -75.77M | -324.57M | 683.52M | -955.48M |
| Financing Cash Flow | -12.12M | 99.29M | 76.23M | 1.66B | 973.69M |
Zhaoke Ophthalmology Ltd. Technical Analysis
Zhaoke Ophthalmology Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$11.94B | 13.90 | 7.25% | 4.10% | -1.81% | -3.79% | |
65 Neutral | HK$1.49B | 36.75 | 4.92% | ― | 38.48% | ― | |
55 Neutral | HK$1.52B | ― | -12.04% | ― | 260.78% | 40.04% | |
55 Neutral | HK$7.40B | ― | -8.04% | ― | 66.72% | 33.68% | |
52 Neutral | $7.53B | 0.20 | -63.81% | 2.31% | 16.15% | 0.40% | |
37 Underperform | HK$1.85B | ― | -228.99% | ― | ― | 44.88% | |
32 Underperform | HK$1.57B | ― | -12.49% | ― | ― | 50.94% |
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology Ltd. announced that the National Medical Products Administration of China has accepted the New Drug Application for NVK002, a novel atropine sulphate eye drop solution for treating myopia progression in children. This development positions the company to potentially address a significant unmet need in China, where myopia is a major health concern affecting millions of children and adolescents. The acceptance of this application marks a significant step forward in the company’s efforts to establish a leading position in the market for myopia control solutions.
Zhaoke Ophthalmology Limited has announced a change in the composition of its Nomination Committee in response to amendments to the Corporate Governance Code, effective from July 1, 2025. The committee now includes Mr. Wong Hin Wing as chairman, along with Prof. Lo Yuk Lam and Ms. Leelalertsuphakun Wanee, reflecting the company’s commitment to aligning with updated governance standards.
Zhaoke Ophthalmology Limited has announced the composition of its board of directors and the roles they hold within the company. The announcement details the members of the board and their respective positions on various committees, which include the Audit, Remuneration, Nomination, Investment, and Executive Committees. This update is crucial for stakeholders as it provides insights into the governance structure and decision-making framework of the company.
Zhaoke Ophthalmology Limited has established a Nomination Committee to oversee the selection and appointment of board members, ensuring a diverse and qualified board composition. The committee will be composed mainly of independent non-executive directors and is tasked with reviewing the board’s structure and recommending changes to align with the company’s corporate strategy.
Zhaoke Ophthalmology Limited has announced that the National Medical Products Administration of China has accepted its Biologics License Application for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first bevacizumab-based antibody filing for wAMD in China, following successful Phase III clinical trials. The company has secured full control over the development and commercialization of TAB014 in China, Hong Kong, and Macau, through an agreement with TOT BIOPHARM Co., Ltd. The acceptance of this application positions Zhaoke Ophthalmology as a significant player in the rapidly growing wAMD market, which is expected to expand significantly by 2030.
Zhaoke Ophthalmology Limited announced that the FDA has cleared its IND application for the CsA Ophthalmic Gel, a core product for treating moderate-to-severe dry eye disease. The gel, which has shown promising results in previous trials, is expected to improve patient compliance due to its once-daily application and rapid onset of action, potentially enhancing the company’s position in the ophthalmic treatment market.
Zhaoke Ophthalmology Limited announced that the National Medical Products Administration of China has accepted its New Drug Application for the CsA Ophthalmic Gel, a treatment for moderate to severe dry eye disease. The gel, which is a proprietary hydrogel formulation, offers improved pharmacokinetic profiles and patient compliance due to its once-daily application and rapid onset of action. This acceptance marks a significant step for the company in enhancing its market position in the ophthalmic industry.
Zhaoke Ophthalmology Ltd. held its Annual General Meeting on May 16, 2025, where all proposed resolutions were passed by the shareholders. Key resolutions included granting mandates to directors for share repurchase and issuance, re-electing directors, and re-appointing KPMG as auditors. The successful passing of these resolutions reflects shareholder confidence and supports the company’s strategic and operational plans.
Zhaoke Ophthalmology Limited has announced its upcoming annual general meeting, scheduled for May 16, 2025, where shareholders will vote on resolutions to authorize the company’s directors to repurchase shares and issue additional shares or securities. These resolutions, if passed, will enable the company to manage its share capital more flexibly, potentially impacting its market positioning and shareholder value.
Zhaoke Ophthalmology Limited has announced the enrollment of the first patient in a Phase III clinical trial for its CsA Ophthalmic Gel, aimed at treating moderate to severe dry eye disease. This trial, involving 360 patients across 25 centers, follows regulatory approval for an Investigational New Drug application. The CsA Ophthalmic Gel, a novel formulation with improved pharmacokinetic profiles, is expected to enhance patient compliance and quality of life by offering a once-daily application with a rapid onset of action, potentially strengthening the company’s position in the expanding dry eye disease market.
Zhaoke Ophthalmology Limited has entered into three distribution agreements with Interpharma to commercialize NVK002, BRIMOCHOL™ PF, and six glaucoma drugs in Thailand. These agreements grant Interpharma exclusive rights to import, distribute, and sell these products, potentially enhancing Zhaoke’s market presence in Southeast Asia and expanding access to innovative ophthalmic treatments.